{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["165(2)"],"submitter":["Harenberg J"],"pubmed_abstract":["New direct and indirect acting factor Xa (FXa) and thrombin inhibitors are being developed to overcome the downsides of the conventional anticoagulants - unfractionated and low molecular weight heparins and vitamin K antagonists. Ximelagatran and idraparinux failed to demonstrate an acceptable safety profile. Rivaroxaban and dabigatran are approved for the post-operative prevention of thromboembolic complications after elective hip or knee replacement surgery; dabigatran is approved for the prevention of embolism in patients with atrial fibrillation in an increasing number of countries. Several novel indirect antithrombin-dependent anticoagulants as well as antithrombin-independent oral direct FXa and thrombin inhibitors are investigated in multiple indications for the prophylaxis and trea"],"journal":["British journal of pharmacology"],"pagination":["363-72"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3268190"],"repository":["biostudies-literature"],"pubmed_title":["New anticoagulants - promising and failed developments."],"pmcid":["PMC3268190"],"pubmed_authors":["Krejczy M","Harenberg J","Wehling M","Marx S"],"additional_accession":[]},"is_claimable":false,"name":"New anticoagulants - promising and failed developments.","description":"New direct and indirect acting factor Xa (FXa) and thrombin inhibitors are being developed to overcome the downsides of the conventional anticoagulants - unfractionated and low molecular weight heparins and vitamin K antagonists. Ximelagatran and idraparinux failed to demonstrate an acceptable safety profile. Rivaroxaban and dabigatran are approved for the post-operative prevention of thromboembolic complications after elective hip or knee replacement surgery; dabigatran is approved for the prevention of embolism in patients with atrial fibrillation in an increasing number of countries. Several novel indirect antithrombin-dependent anticoagulants as well as antithrombin-independent oral direct FXa and thrombin inhibitors are investigated in multiple indications for the prophylaxis and trea","dates":{"release":"2012-01-01T00:00:00Z","publication":"2012 Jan","modification":"2025-04-05T10:37:11.476Z","creation":"2019-03-27T00:48:32Z"},"accession":"S-EPMC3268190","cross_references":{"pubmed":["21740405"],"doi":["10.1111/j.1476-5381.2011.01578.x"]}}